Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Kahla, Germany Clinical Trials

A listing of Kahla, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

Durvalumab and Tremelimumab for Pediatric Malignancies

This is a first time in pediatrics study primarily designed to evaluate the safety and tolerability of durvalumab and durvalumab in combination with tremelimumab at increasing doses in pediatric patients with advanced solid malignancies and hematological malignancies (including lymphomas) and for whom no standard of care treatments exist. Although treatment …

Phase

6.16 miles

Learn More »

Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD

This is an interventional, open-label, phase I/IIa clinical trial to investigate the efficacy and safety of up to four doses of the IMP topically administered on the target eye of patients with LSCD. Patients will be treated in up to four ascending dose groups. The allogeneic investigational product LSC2 contains …

Phase

6.16 miles

Learn More »

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

The purpose of this study is to investigate the safety, pharmacokinetics and preliminary efficacy of combinations treatment of ruxolitinib with 3 novel compounds: siremadlin, crizanlizumab and MBG453 in myelofibrosis (MF) subjects.

Phase

8.77 miles

Learn More »

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of …

Phase

8.77 miles

Learn More »

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients. Dosages of the drugs are derived from previous Phase-I/II studies; ruxolitinib treatment will be started at 10 mg twice daily, whereas the dose of …

Phase

8.77 miles

Learn More »